首页> 外文OA文献 >Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y
【2h】

Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y

机译:受体亚型Y1和Y5参与神经肽Y的肾脏作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. Systemic infusion of neuropeptide Y (NPY) reduces renal blood flow and can concomitantly increase diuresis, natriuresis and calciuresis in anaesthetized rats. The present study was designed to investigate whether the apparently contradictory NPY effects on renal blood flow and urine formation and composition are mediated by distinct NPY receptor subtypes. 2. NPY and its analogues, peptide YY (PYY), [Leu31, Pro34]NPY and NPY13-36, were infused in incremental doses of 0.3, 1 and 3 micrograms kg-1 min-1 for 45 min each and the results compared to those obtained in vehicle-infused rats. Renal blood flow was monitored in 1-5 min intervals, while urine excretion and composition were determined in 15 min collection periods. Plasma renin activity and aldosterone concentrations were measured at the end of the final infusion period. 3. Relative to vehicle NPY, PYY and [Leu31, Pro34]NPY dose-dependently reduced renal blood flow and increased diuresis, natriuresis and calciuresis with roughly similar potency; NPY13-36 slightly but significantly increased renal blood flow but had no effect on diuresis, natriuresis and calciuresis. None of the peptides significantly affected endogenous creatinine clearance or kaliuresis. 4. Plasma renin activity was significantly reduced by PYY. Quantitatively similar reductions were observed with NPY and [Leu31, Pro34]NPY but failed to reach statistical significance with the given number of experiments. NPY13-36 did not reduce plasma renin activity. None of the peptides significantly affected plasma aldosterone concentrations. 5. In another series of experiments infusion of PYY3-36 (2 micrograms kg-1 min-1 for 120 min) did not reduce renal blood flow but significantly enhanced diuresis and natriuresis to a similar extent as the NPY 2 micrograms kg-1 min-1. 6. In a final series of experiments the Y1-selective antagonist, BIBP 3226 (1 or 10 micrograms kg-1 min-1) dose-dependently antagonized reductions of renal blood flow elicited by bolus injections of NPY (0.1-30 micrograms kg-1). BIBP 3226 (10 micrograms kg-1 min-1) also inhibited the effects of a 120 min infusion of NPY (2 micrograms kg-1 min-1) on renal blood flow but had only minor inhibitory effects on enhancements of diuresis and did not significantly affect enhancements of natriuresis. 7. We conclude that NPY reduces renal blood via a classical Y1 subtype of NPY receptor. In contrast enhancements of diuresis, natriuresis and calciuresis occur via a distinct subtype which resembles the receptor that mediates NPY-induced enhancement of food intake
机译:1.全身输注神经肽Y(NPY)可以减少肾脏血流量,并可以同时增加麻醉大鼠的利尿,利钠和钙化作用。本研究旨在调查是否明显不同的NPY受体亚型介导了明显矛盾的NPY对肾血流量,尿液形成和成分的影响。 2. NPY及其类似物肽YY(PYY),[Leu31,Pro34] NPY和NPY13-36分别以0.3、1和3微克kg-1 min-1的剂量注入,每次45分钟,比较结果与那些在媒介物注入的大鼠中获得的结果相同。每隔1-5分钟监测一次肾脏血流,在每15分钟收集一次尿液中排泄尿液和组成。在最后输注期结束时测量血浆肾素活性和醛固酮浓度。 3.相对于赋形剂NPY,PYY和[Leu31,Pro34] NPY,剂量依赖性地减少了肾血流量,并增加了利尿,利尿和利尿作用,其药效大致相似。 NPY13-36略有增加肾血流量,但对利尿,利尿和利尿无影响。没有一种肽显着影响内源性肌酐清除率或卡利尿病。 4. PYY显着降低血浆肾素活性。在NPY和[Leu31,Pro34] NPY上观察到定量相似的减少,但在给定的实验数量下未能达到统计学意义。 NPY13-36不会降低血浆肾素活性。没有一种肽显着影响血浆醛固酮浓度。 5.在另一系列实验中,输注PYY3-36(2微克kg-1分钟-1,持续120分钟)并没有减少肾血流量,但显着增强了利尿和利尿作用,其程度与NPY 2微克kg-1分钟-1类似。 -1。 6.在最后一系列实验中,Y1选择性拮抗剂BIBP 3226(1或10微克kg-1 min-1)剂量依赖性拮抗大剂量推注NPY(0.1-30微克kg- 1)。 BIBP 3226(10毫克kg-1 min-1)也抑制了120分钟的NPY输注(2毫克kg-1 min-1)对肾脏血流的影响,但对利尿作用的增强只有很小的抑制作用,而没有严重影响利尿作用。 7.我们得出结论,NPY通过经典的NPY受体Y1亚型减少肾脏血液。相比之下,利尿,利尿和钙尿的增强是通过独特的亚型发生的,该亚型类似于介导NPY诱导食物摄取增强的受体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号